Graft‐versus‐leukaemia immunity is retained following treatment with post‐transplant cyclophosphamide alone or combined with tocilizumab in humanised mice
Abstract Objectives Donor haematopoietic stem cell transplantation treats leukaemia by inducing graft‐versus‐leukaemia (GVL) immunity. However, this benefit is often mitigated by graft‐versus‐host disease (GVHD), which is reduced by post‐transplant cyclophosphamide (PTCy) alone or combined with tocilizumab (TOC) in humanised mice. This study established a preclinical humanised mouse model of GVL and investigated whether PTCy alone or combined with TOC impacts GVL immunity. Methods NOD‐scid‐IL2Rγnull mice were injected with 2 × 107 human peripheral blood mononuclear cells (hPBMCs) on day 0 and with 1 × 106 THP‐1 acute myeloid leukaemia cells on day 14. In subsequent experiments, mice were also injected with PTCy (33 mg kg−1) or Dulbecco's phosphate buffered saline (PBS) on days 3 and 4, alone or combined with TOC or control antibody (25 mg kg−1) twice weekly for 28 days. Clinical signs of disease were monitored until day 42. Results Mice with hPBMCs from three different donors and THP‐1 cells showed similar survival, clinical score and weight loss. hCD33+ leukaemia cells were minimal in mice reconstituted with hPBMCs from two donors but present in mice with hPBMCs from a third donor, suggesting donor‐specific GVL responses. hPBMC‐injected mice treated with PTCy alone or combined with TOC (PTCy + TOC) demonstrated prolonged survival compared to control mice. PTCy alone and PTCy + TOC‐treated mice with hPBMCs showed minimal hepatic hCD33+ leukaemia cells, indicating sustained GVL immunity. Further, the combination of PTCy + TOC reduced histological damage in the lung and liver. Conclusion Collectively, this research demonstrates that PTCy alone or combined with TOC impairs GVHD without compromising GVL immunity..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Clinical & Translational Immunology - 13(2024), 3, Seite n/a-n/a |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Chloe Sligar [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Graft‐versus‐leukaemia |
|---|
| doi: |
10.1002/cti2.1497 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ092439659 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ092439659 | ||
| 003 | DE-627 | ||
| 005 | 20240412123124.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240412s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/cti2.1497 |2 doi | |
| 035 | |a (DE-627)DOAJ092439659 | ||
| 035 | |a (DE-599)DOAJff78bb68913b4966b944916c5799b624 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a RC581-607 | |
| 100 | 0 | |a Chloe Sligar |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Graft‐versus‐leukaemia immunity is retained following treatment with post‐transplant cyclophosphamide alone or combined with tocilizumab in humanised mice |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Objectives Donor haematopoietic stem cell transplantation treats leukaemia by inducing graft‐versus‐leukaemia (GVL) immunity. However, this benefit is often mitigated by graft‐versus‐host disease (GVHD), which is reduced by post‐transplant cyclophosphamide (PTCy) alone or combined with tocilizumab (TOC) in humanised mice. This study established a preclinical humanised mouse model of GVL and investigated whether PTCy alone or combined with TOC impacts GVL immunity. Methods NOD‐scid‐IL2Rγnull mice were injected with 2 × 107 human peripheral blood mononuclear cells (hPBMCs) on day 0 and with 1 × 106 THP‐1 acute myeloid leukaemia cells on day 14. In subsequent experiments, mice were also injected with PTCy (33 mg kg−1) or Dulbecco's phosphate buffered saline (PBS) on days 3 and 4, alone or combined with TOC or control antibody (25 mg kg−1) twice weekly for 28 days. Clinical signs of disease were monitored until day 42. Results Mice with hPBMCs from three different donors and THP‐1 cells showed similar survival, clinical score and weight loss. hCD33+ leukaemia cells were minimal in mice reconstituted with hPBMCs from two donors but present in mice with hPBMCs from a third donor, suggesting donor‐specific GVL responses. hPBMC‐injected mice treated with PTCy alone or combined with TOC (PTCy + TOC) demonstrated prolonged survival compared to control mice. PTCy alone and PTCy + TOC‐treated mice with hPBMCs showed minimal hepatic hCD33+ leukaemia cells, indicating sustained GVL immunity. Further, the combination of PTCy + TOC reduced histological damage in the lung and liver. Conclusion Collectively, this research demonstrates that PTCy alone or combined with TOC impairs GVHD without compromising GVL immunity. | ||
| 650 | 4 | |a graft‐versus‐leukaemia | |
| 650 | 4 | |a humanised mice | |
| 650 | 4 | |a post‐transplant cyclophosphamide | |
| 650 | 4 | |a tocilizumab | |
| 650 | 4 | |a xenogeneic graft‐versus‐host disease | |
| 653 | 0 | |a Immunologic diseases. Allergy | |
| 700 | 0 | |a Ellie Reilly |e verfasserin |4 aut | |
| 700 | 0 | |a Peter Cuthbertson |e verfasserin |4 aut | |
| 700 | 0 | |a Kara L Vine |e verfasserin |4 aut | |
| 700 | 0 | |a Katrina M Bird |e verfasserin |4 aut | |
| 700 | 0 | |a Amal Elhage |e verfasserin |4 aut | |
| 700 | 0 | |a Stephen I Alexander |e verfasserin |4 aut | |
| 700 | 0 | |a Ronald Sluyter |e verfasserin |4 aut | |
| 700 | 0 | |a Debbie Watson |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Clinical & Translational Immunology |d Wiley, 2015 |g 13(2024), 3, Seite n/a-n/a |w (DE-627)DOAJ000011428 |x 20500068 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2024 |g number:3 |g pages:n/a-n/a |
| 856 | 4 | 0 | |u https://doi.org/10.1002/cti2.1497 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/ff78bb68913b4966b944916c5799b624 |z kostenfrei |
| 856 | 4 | 0 | |u https://doi.org/10.1002/cti2.1497 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2050-0068 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2024 |e 3 |h n/a-n/a | ||